Abstract
The better understanding of the genetic contribution for HF and the correlation between the HF genotypes and phenotypes will allow the prior identification of patients with the highest risk of CVD development, allowing a more efficient clinical and therapeutic follow-up, besides contributing to the development of more efficient and specific pharmacotherapies. Usually, the diagnosis of FH …